M+ Rhusigen®
Pharmaceutical Name
Erysipelothrix rhusiopathiae-Mycoplasma hyopneumoniae Bacterin
Features and Benefits- The first Erysipelas vaccine USDA licensed to provide protection against both mortality and clinical symptoms caused by Erysipelas in swine
- Contains the exclusive safe and smooth Emunade® adjuvant
- Delivers protection against Erysipelothrix rhusiopathiae infection through the growing period
- Protects against mycoplasma pneumonia - one of the most economically significant disease-associated conditions in swine production.
- In tests conducted by independent research facilities, M+PAC - vaccinated pigs demonstrated:
- higher antibody titers
- numerically lower lung lesion scores
- less coughing
- numerically higher cell-mediated immunity
Indications
Recommended for use as an aid in the prevention of disease and mortality associated with Erysipelothrix rhusiopathiae and to aid in the prevention of pneumonia caused by Mycoplasma hyopneumoniae infection in swine.
WARNING: Extreme caution should be used when injecting oil emulsion vaccines to avoid injecting your own finger or hand. Accidental injection can cause serious local reaction. Contact a physician immediately if accidental injection occurs.
Dosage
For further information including dose rate and complete directions and warnings, please see the Product Label by clicking here.
M+ RHUSIGEN is a registered trademark of Schering-Plough Animal Health Corporation.
